In this article, we discuss the newest stocks in Michael Burry’s portfolio. You can skip our detailed analysis of Michael Burry’s hedge fund and its returns, and go directly to read Michael Burry Stock Portfolio: 5 Newest Additions in 2021.
Michael Burry made his name during the financial crisis of 2008 by making profits during a time when most of his peers suffered heavily. Born in California, Burry is an American investor, physician, and hedge fund manager. Currently, he manages Scion Asset Management, which he founded in 2013.
Scion Asset Management mainly invests in services, technology, finance, and consumer goods sector as of Q2. The fund has a portfolio value of over $2 billion, up from $1.3 billion in the previous quarter. Some of the notable stocks in Burry’s portfolio include Facebook, Inc. (NASDAQ:FB), Alphabet Inc. (NASDAQ:GOOG), Walmart Inc. (NYSE:WMT), and The Kraft Heinz Company (NASDAQ:KHC). In this article, we will focus on the newest additions in the investor’s portfolio.
Our Methodology:
Let’s analyze our list of the newest stocks in Michael Burry’s portfolio. The stocks mentioned below have been added to Scion Asset Management’s 13F portfolio in Q1 and Q2 of 2021.
Michael Burry of Scion Asset Management
Why pay attention to hedge fund sentiment while choosing stocks?
Insider Monkey’s research was able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by wide margins. Between March 2017 and July 2021, our monthly newsletter’s stock picks returned 186.1%, vs. 100.1% for the S&P 500 ETF (SPY). Our stock picks outperformed the market by more than 86 percentage points (see the details here). That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to. You can subscribe to our free newsletter on our homepage to receive our stories in your inbox.
Michael Burry Stock Portfolio: 10 Newest Additions in 2021
10. Vy Global Growth (NYSE:VYGG)
Scion Asset Management’s Stake Value as of Q2: $1,438,000
Percent of Scion Asset Management’s 13F Portfolio: 0.06%
Number of Hedge Fund Holders: 35
Vy Global Growth (NYSE:VYGG) is a blank check company that went public last year and aims to acquire technology businesses. In Q2 2021, Scion Asset Management bought 144,550 shares in the company, valued at over $1.4 million.
As of Q2 2021, 35 hedge funds tracked by Insider Monkey have positions in Vy Global Growth (NYSE:VYGG), valued at $281.4 million.
Weiss Asset Management is the leading shareholder of Vy Global Growth (NYSE:VYGG), with shares worth $31.5 million.
9. Golden Ocean Group Limited (NASDAQ:GOGL)
Scion Asset Management’s Stake Value as of Q2: $7,728,000
Percent of Scion Asset Management’s 13F Portfolio: 0.37%
Number of Hedge Fund Holders: 15
Golden Ocean Group Limited (NASDAQ:GOGL), a Bermuda-based bulk shipping company, reported a 137% growth in revenue in Q2 2021, at $275.5 million.
This September, HC Wainwright initiated its coverage on Golden Ocean Group Limited (NASDAQ:GOGL) with a Neutral rating and a $13 price target.
Scion Asset Management bought 530,000 shares in Golden Ocean Group Limited (NASDAQ:GOGL) in Q1 2021, valued at $3.5 million. The hedge fund increased its stake in the company by 33%, buying an additional 170,000 shares in Q2, taking the total to 700,000 shares, worth $7.7 million.
As of Q2 2021, 15 hedge funds tracked by Insider Monkey have positions in Golden Ocean Group Limited (NASDAQ:GOGL), valued at $133.3 million. In the previous quarter, 11 hedge funds had stakes in the company, worth $62.1 million.
Like Tesla, Inc. (NASDAQ:TSLA), Facebook, Inc. (NASDAQ:FB), Alphabet Inc. (NASDAQ:GOOG), Walmart Inc. (NYSE:WMT), and The Kraft Heinz Company (NASDAQ:KHC), Golden Ocean Group Limited (NASDAQ:GOGL) is also one of the notable stocks to invest in.
8. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)
Scion Asset Management’s Stake Value as of Q2: $11,213,000
Percent of Scion Asset Management’s 13F Portfolio: 0.53%
Number of Hedge Fund Holders: 13
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is a clinical-stage biopharmaceutical company that develops Ganaxolone, a drug used to treat seizures. In August, the company’s Phase 2 study of Ganaxolone reported 16.6% seizure reduction and was noted as ‘impressive’ by Truist’s analyst Joon Lee, who lifted the firm’s price target on Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) to $40, while keeping a Buy rating on the shares.
Lion Point is the largest shareholder of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), with over 3.6 million shares. Overall, 13 hedge funds reported owning stakes in the company in Q2, valued at $243.3 million.
Scion Asset Management started building its position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) in Q1 2021, with shares worth $4.6 million. In Q2, the hedge fund increased its position in the company by 111%, owning 625,000 shares, valued at $11.2 million. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) represents 0.53% of the hedge fund’s 13F portfolio.
Like Tesla, Inc. (NASDAQ:TSLA), Facebook, Inc. (NASDAQ:FB), Alphabet Inc. (NASDAQ:GOOG), Walmart Inc. (NYSE:WMT), and The Kraft Heinz Company (NASDAQ:KHC), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is also one of the notable stocks in 2021.
7. Scorpio Tankers Inc. (NYSE:STNG)
Scion Asset Management’s Stake Value as of Q2: $13,230,000
Percent of Scion Asset Management’s 13F Portfolio: 0.63%
Number of Hedge Fund Holders: 20
Scion Asset Management bought stakes in the Monaco-based tanker shipping company, Scorpio Tankers Inc. (NYSE:STNG), in Q1, valued at $3.5 million. In Q2, the hedge fund bought additional 409,900 shares in the company, increasing its position by 216%. These stakes are valued at over $13.2 million. Scorpio Tankers Inc. (NYSE:STNG) represents 0.63% of Scion Asset Management’s 13F portfolio.
6. CVS Health Corporation (NYSE:CVS)
Scion Asset Management’s Stake Value as of Q2: $16,688,000
Percent of Scion Asset Management’s 13F Portfolio: 0.8%
Number of Hedge Fund Holders: 67
In Q2 2021, Harris Associates is the largest shareholder of CVS Health Corporation (NYSE:CVS) with shares worth $713 million. The hedge fund sentiment was positive for the company in Q2, as 67 hedge funds tracked by Insider Monkey have stakes in CVS Health Corporation (NYSE:CVS), up from 61 in the previous quarter. The total value of these stakes is $1.35 billion.
CVS Health Corporation (NYSE:CVS) was Morgan Stanley’s top pick in the Healthcare Services and Distribution segment for the rest of 2021. In September, the firm lifted its price target on CVS Health Corporation (NYSE:CVS) to $114, while keeping an Overweight rating on the shares.
Scion Asset Management bought 110,000 shares in CVS Health Corporation (NYSE:CVS) in Q1, with an estimated average price of $72.86 per share. In Q2, the hedge fund increased its activity in the company by 82%, and now owns 200,000 shares in the company, valued at $16.6 million. CVS Health Corporation (NYSE:CVS) accounts for 0.8% of the fund’s 13F portfolio.
ClearBridge Investments mentioned CVS Health Corporation (NYSE:CVS) in its Q2 2021 investor letter. Here is what the firm has to say:
“Our differentiated positions in the health care sector also made strong contributions as the market began to reward the heavily discounted sector.CVS Health saw strength in its pharmacy benefits manager business as well as its managed care business, Aetna, helping to confirm our positive view of CVS’s repositioning of its business model from a dispensary model to a service model. With CVS store-based health care services offering patients better convenience, encouraging better health care compliance and ultimately lower costs, we believe the company is at the forefront of a changing mindset in the health care services sector.”
Click to continue reading and see Michael Burry Stock Portfolio: 5 Newest Additions in 2021.
Suggested articles:
- Michael Burry’s Top Stock Picks
- Michael Burry’s New Stock Picks
- Michael Burry is Shorting Tesla and Buying These 10 Stocks Instead
Disclosure. None. Michael Burry Stock Portfolio: 10 Newest Additions in 2021 is originally published on Insider Monkey.
